Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

• Published in: European journal of cancer (1990) Vol. 123; pp. 162 - 170
• Main Authors: Sharma, Atul, Kalyan Mohanti, Bidhu, Pal Chaudhary, Surendra, Sreenivas, V., Kumar Sahoo, Ranjit, Kumar Shukla, Nootan, Thulkar, Sanjay, Pal, Sujoy, Deo, Surya V., Pathy, Sushmita, Ranjan Dash, Nihar, Kumar, Sunil, Bhatnagar, Sushma, Kumar, Rakesh, Mishra, Seema, Sahni, Peush, Iyer, Venkateswaran K., Raina, Vinod
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.12.2019; Elsevier Science Ltd
• Subjects: Cancer; Chemotherapy; Cisplatin; Confidence intervals; Equivalence; Gallbladder; Gallbladder cancer; Gemcitabine; Oncology; Oxaliplatin; Patients; Peripheral neuropathy; Randomization; Thrombocytopenia; Toxicity; Oxaliplatin; Gemcitabine; Equivalence; Gallbladder cancer; Cisplatin

To determine equivalence of modified gemcitabine and oxaliplatin compared with gemcitabine and cisplatin in unresectable gallbladder cancer (GBC). Primary end-point was overall survival (OS). Open label, prospective, randomised phase III equivalence study. Inclusion criteria included histologically...